In the US,<unk>  is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults or for the treatment of primary progressive MS, in adults. It is administered by intravenous infusion. In the EU,<unk>  is indicated for the treatment of adults with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features and for the treatment of adults with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.
Ocrelizumab
Risankizumab
Ibalizumab
Theralizumab
Brolucizumab
Atezolizumab
Inebilizumab
Etaracizumab